Tolerogenixx Expands Phase Ii Immune-Tolerance Trial And Closes Eur 12 Million Series A Financing
Amount Raised
€12 Million
Round Type
Series A
HeidelbergBiotechnologyHealth CareTherapeuticsDescription
Heidelberg, July 6, 2023 – TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced that in the TOL2- Phase IIb study in renal transplant patients TolerogenixX has received green light by the Safety Board to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression drugs, reducing tacrolimus and weaning off enteric-coated mycophenolate sodium and methylprednisolone completely. The study enrolls 63 transplant couples consisting of a donor and a transplant recipient, respectively. The protocol has been published in BMJ Open.
Quick answer
TolerogenixX raised €12 Million in a Series A round, dated July 6, 2023. TolerogenixX is based in Heidelberg, Baden Württemberg, Germany.
- How much did TolerogenixX raise?
- TolerogenixX raised €12 Million in a Series A round on July 6, 2023.
- What does TolerogenixX do?
- TolerogenixX vision is to innovate Immunosuppression with its newly developed MIC Cell Treatments.
- Where is TolerogenixX based and how big is it?
- TolerogenixX is based in Heidelberg, Baden Württemberg, Germany.
- Who are the decision-makers at TolerogenixX?
- Fundz holds 1 contact at TolerogenixX. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as TolerogenixX that raised within 45 days of this round, from Fundz verified event records.
- Abcuro raised $155M (Series B) on August 17, 2023.
- MindMed raised $7M on August 11, 2023.
- Abcuro raised $120M on August 11, 2023.
- ADARx Pharmaceuticals, Inc. raised $200M (Series C) on August 9, 2023.
- Alltrna raised an undisclosed amount (Series B) on August 9, 2023.
- Fore Biotherapeutics raised $62M on August 9, 2023.
Who to call at TolerogenixX, and when
A new round usually means TolerogenixX is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day TolerogenixX raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at TolerogenixX, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at TolerogenixX. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment TolerogenixX raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTolerogenixX raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.